LBA
WX

Letko, Brosseau & Associates’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Letko, Brosseau & Associates’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,200
Closed -$1.3M – 109
2015
Q3 		$1.3M Sell
30,200
-219,800
-88% -$9.28M 0.01% 85
2015
Q2 		$10.6M Hold
250,000
– – 0.1% 76
2015
Q1 		$9.7M Hold
250,000
– – 0.09% 75
2014
Q4 		$8.42M Hold
250,000
– – 0.07% 77
2014
Q3 		$8.76M Hold
250,000
– – 0.07% 79
2014
Q2 		$8.21M Hold
250,000
– – 0.07% 78
2014
Q1 		$9.21M Sell
250,000
-106,401
-30% -$3.9M 0.08% 77
2013
Q4 		$13.7M Hold
356,401
– – 0.11% 73
2013
Q3 		$9.77M Buy
356,401
+15,000
+4% +$355K 0.09% 72
2013
Q2 		$7.17M Buy
+341,401
New +$6.67M 0.07% 74

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Letko, Brosseau & Associates's WX Position: Q4 2015 in Review

Letko, Brosseau & Associates sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 30,200 shares — an estimated $1.3M sold.

Letko, Brosseau & Associates first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $13.7M in Q4 2013. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Letko, Brosseau & Associates reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Letko, Brosseau & Associates sold 30,200 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $1.3M.
  • Letko, Brosseau & Associates first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Letko, Brosseau & Associates's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $13.7M in Q4 2013.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Letko, Brosseau & Associates's 13F filing for Q4 2015, filed 8 Feb 2016.